<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831464</url>
  </required_header>
  <id_info>
    <org_study_id>RenoMet</org_study_id>
    <nct_id>NCT03831464</nct_id>
  </id_info>
  <brief_title>Metformin as RenoProtector of Progressive Kidney Disease</brief_title>
  <acronym>RenoMet</acronym>
  <official_title>Metformin as RenoProtector in Non-Diabetic Patients With Progressive Chronic Kidney Disease (CKD Stages 2, 3A and 3B): a Multi-centre, Practice-oriented, Repurposing, Double-blind, Placebo-controlled, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled,&#xD;
      randomized clinical trial. The RenoMet trial is repurposing an already approved agent&#xD;
      (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients&#xD;
      (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant&#xD;
      for more than 3 years).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention consists in the treatment of patients with progressive kidney disease and&#xD;
      blindly randomized to the treatment group with metformin as medication, added to their usual&#xD;
      treatment. Metformin is a well-known and cheap medication used for many years and still used&#xD;
      as main treatment of type 2 diabetes. In our study, this 'old' product will be used for a&#xD;
      'new' indication, slowing down the progression of CKD. After randomization in the&#xD;
      participating renal care clinic, patients in the intervention group will be treated with&#xD;
      metformin at a dose of 1000 mg/day (2x500mg) in the evening during 30 months (Metformin -&#xD;
      Glucophage SR (Merck KGaA)). During the first month of the trial a dose of 1x500mg will be&#xD;
      used in order to avoid as much as possible some well-known mainly gastrointestinal side&#xD;
      effects of metformin treatment At each visit during the study period, the metformin&#xD;
      medication will be hand over to the patient in a HDPE bottle, closed with a MEMS cap&#xD;
      (Medication Event Monitoring System). The MEMS a cap that registers the time and date of each&#xD;
      opening (presumed intake of the medication in the bottle).&#xD;
&#xD;
      Patients blindly randomized to the control group will receive placebo treatment (2 tablets&#xD;
      per day) also in a MEMS device and will continue to receive usual care. Control patients will&#xD;
      have the same data collection.&#xD;
&#xD;
      Follow-up of patients during the entire study period will be the responsibility of the&#xD;
      treating nephrologist in the renal care clinic. All patients will have a baseline data&#xD;
      collection at study entry (demographics, comorbidities, concomitant medication, clinical&#xD;
      parameters, lab results). During the study period of 30 months patients will have follow-up&#xD;
      visits at their renal care clinic every four months with collection of follow-up data&#xD;
      (concomitant medication, clinical parameters, routine lab results and drug related problems).&#xD;
      Extra blood and urine samples will be collected for a centralized second determination of&#xD;
      serum creatinine and proteinuria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR) in a new indication (renoprotection) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years),</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reaching a 30% decline of eGFR</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>Values of serum creatinine obtained from local determination will be used for the calculation of eGFR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate during the investigation period</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>The time to the event of all-cause mortality will be compared between Metformin and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the renal function</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>Expressed as the slopes of the 8 eGFR determinations during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients developing end-stage renal disease</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>The time to development a doubling of serum creatinine or end-stage renal failure will be compared between Metformin and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of transplant patients with graft loss</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>The time to the event of graft loss will be compared in the Transplant group between Metformin and placebo using a log-rank test. Kaplan Meier curves will be used to describe the data graphically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of proteinuria</measure>
    <time_frame>Difference between baseline and study end</time_frame>
    <description>This will be examined by a generalized linear mixed models using baseline measurement and study end measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of hypertension</measure>
    <time_frame>Difference between baseline and study end</time_frame>
    <description>This will be examined by a generalized linear mixed models using baseline measurement and study end measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Major Adverse Cardiovascular Events</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>This will be examined by a generalized linear mixed models using baseline measurement and study end measurement. This model will allow inclusion of correcting variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization during the investigation period</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>Hospitalization during the investigation period will be studied using a Cox regression with multiple events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization during the investigation period</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>Total number of hospitalization days will be analyzed using a multiple regression model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) Adverse drug events</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>Number of lactic acidosis events, number of deaths related to lactic acidosis, other adverse events. Reported selected AEs and all SAEs will be summarized using descriptive statistics and a comparison between Metformin and placebo group will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Quality of life</measure>
    <time_frame>Period of 30 months</time_frame>
    <description>During the study period (area under the curve as well as difference between baseline and study end) of the utility Qol score of the EQ-5D-5L questionnaire. Quality of life as measured during the follow-up visits as well as the evolution of Qol during the trial will be compared between Metformin and placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Metformin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.&#xD;
During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .</description>
    <arm_group_label>Metformin treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.</description>
    <arm_group_label>Placebo control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Seen on a regular base in one of the participating outpatient clinics of renal care&#xD;
             with a previous consultation within the last year&#xD;
&#xD;
          -  Having a chronic kidney disease (including having a transplant kidney for more than 3&#xD;
             years) with:&#xD;
&#xD;
               -  a CKD stage 2, 3A or 3B ( i.e. with estimated glomerular filtration rate (eGFR)&#xD;
                  between 30 and 90 ml/min/1.73m2) at the time of the baseline visit&#xD;
&#xD;
               -  showing a decline of eGFR between 2.0 and 20.0 ml/min/year determined using at&#xD;
                  least three determinations of eGFR (CKD-Epi formula) whereby the oldest one&#xD;
                  should be from more than 1 year ago and the most recent will be the one of the&#xD;
                  baseline visit. For transplant patients the decline will be based on serum&#xD;
                  creatinine values determined during the preceding 24 months. For all other&#xD;
                  patients, the decline will be based on values determined within the last five&#xD;
                  years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Illiteracy: patients not knowing how to read or write&#xD;
&#xD;
          2. Patients not able to communicate in Dutch or French&#xD;
&#xD;
          3. Patients with mental deterioration, incapable to give informed consent and to&#xD;
             understand the safety instructions of the study (at the discretion of the treating&#xD;
             nephrologist)&#xD;
&#xD;
          4. Patients with one of the following clinical problems:&#xD;
&#xD;
               -  Patients with nephrotic syndrome&#xD;
&#xD;
               -  Patients showing a fast decline of renal function (more than 20 ml/min/year)&#xD;
                  during the preceding five years&#xD;
&#xD;
               -  Diabetes mellitus (any type: 1, 2, Maturity Onset Diabetes of the Young (MODY),&#xD;
                  New Onset Diabetes After Transplantation (NODAT)) confirmed by a glycemia level &gt;&#xD;
                  125 mg/dl (7.0 mmol/L) after a fasting time of 8 hours&#xD;
&#xD;
               -  Patients with a renal transplantation for less than 3 years&#xD;
&#xD;
               -  Patients with multi-organ transplantation&#xD;
&#xD;
               -  History of solid organ transplantation&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease ( COPD) stage Gold IV (Oxygene-dependency)&#xD;
&#xD;
               -  Congestive heart failure (NYHA stage IV)&#xD;
&#xD;
               -  Inflammatory bowel disease (IBD)&#xD;
&#xD;
               -  Stoma&#xD;
&#xD;
               -  Hepatic insufficiency or cirrhosis, acute alcohol intoxication or alcoholism (&gt;&#xD;
                  20 glasses of alcoholic beverages per week)&#xD;
&#xD;
               -  History of metabolic diseases (e.g. mitochondrial encephalomyopathy (MELAS),&#xD;
                  lactic acidosis, stroke-like episodes, etc…)&#xD;
&#xD;
               -  Pregnancy and/or lactating women at the time of recruitment and during the study&#xD;
                  period&#xD;
&#xD;
               -  Patient with prior use of metformin within the past 12 months (e.g. glucose&#xD;
                  intolerance, polycystic ovary syndrome, etc…) or with other study medication&#xD;
                  taken within the framework of another clinical trial&#xD;
&#xD;
          5. Patients showing elevated blood lactate level(s) at the time of recruitment (i.e. a&#xD;
             confirmed lactate level ≥ 2.5 mmol/L at baseline and a confirmed lactate level ≥ 2.5&#xD;
             mmol/L after 4 weeks (±1 week))&#xD;
&#xD;
          6. Patients showing a confirmed (after 3 months) serum bicarbonate level &lt; 22 mmol/L (or&#xD;
             &lt; 20 mmol/L if delay of more than 1 hour between sampling and determination)&#xD;
&#xD;
          7. Hypersensitivity to metformin or to any of the excipients listed in section 6.1 of the&#xD;
             Glucophage SR SmPC&#xD;
&#xD;
          8. One of the following diseases during the previous 6 months: myocardial infarction,&#xD;
             shock, acute problems of decompensated heart failure or respiratory failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc De Broe, Professor</last_name>
    <phone>0486 84 32 82</phone>
    <email>marc.debroe@uantwerpen.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bart Maes, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Vanacker, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVZ Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bruno Van Vlem, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epicura Ath</name>
      <address>
        <city>Ath</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric Debelle, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epicura Baudour</name>
      <address>
        <city>Baudour</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabrice Gankam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wim Lemahieu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain Le Moine, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric Collart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lissa Pipeleers, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-François Cambier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ester Philipse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francis Verbeke, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan Vanwalleghem, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional de la Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier Warling, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Liège (CHU Liège)</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Jouret, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional de Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benoit Georges, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kirstine Dyckmans, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Wallonie Picarde</name>
      <address>
        <city>Tournai</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Boesmans, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Arnouts, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Verviers</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Christine Parotte, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Prof Dr. Marc De Broe</investigator_full_name>
    <investigator_title>Prof Dr.</investigator_title>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Metformin</keyword>
  <keyword>Renoprotector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

